Drug Trial Radar · NCT00853970
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Last checked: Nov 20, 2026Latest source record: Jan 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
299
Actual
Start
Feb 2009
Primary completion
Sep 2009
Study completion Dec 2009
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Mar 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery
Conditions
- Pain
- Inflammation
Interventions
Bromfenac Ophthalmic SolutionDrug
sterile ophthalmic solution
Placebo ComparatorDrug
sterile ophthalmic solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summed Ocular Inflammation Score (SOIS) of ZeroTime frame: Day 15 (Primary Endpoint)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ISTA Pharmaceuticals, Inc.
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.